Literature DB >> 9517617

Vitamin D binding protein variants and the risk of COPD.

D Schellenberg1, P D Paré, T D Weir, J J Spinelli, B A Walker, A J Sandford.   

Abstract

Although the development of chronic obstructive pulmonary disease (COPD) in smokers shows genetic susceptibility, only alpha1-antitrypsin deficiency has been identified as a definite genetic risk factor. There have been three previous studies in which associations between Gc-globulin phenotypes and COPD have been investigated. Although some data suggest an association, the results were inconclusive. Because smoking is the major risk factor for COPD, it may have been a confounding factor in previous studies. We have investigated Gc-globulin genotypic frequencies among 75 COPD patients and 64 nonobstructed controls. Both groups had significant smoking histories: pack-years (mean +/- SD) of 52 +/- 30 and 48 +/- 27, respectively. The results show that homozygosity for the Gc2 allele is protective against COPD (OR = 0.17, 95% CI = 0.03 to 0.83). There were no differences between genotypes for lung elastic recoil values or for the level of upstream airway resistance. Gc-globulin can enhance complement (C5a)-mediated neutrophil chemotaxis. Because neutrophils play a role in parenchymal destruction and airway inflammation, we examined whether Gc-globulin's ability to enhance neutrophil chemotaxis varied with genotype. We found no difference among genotypes with respect to neutrophil chemotaxis suggesting that the protective effect of the Gc2 allele is mediated through a different mechanism.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9517617     DOI: 10.1164/ajrccm.157.3.9706106

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  33 in total

Review 1.  Genetics and pulmonary medicine. 9. Molecular genetics of chronic obstructive pulmonary disease.

Authors:  P J Barnes
Journal:  Thorax       Date:  1999-03       Impact factor: 9.139

2.  Cigarette smoke-induced pulmonary inflammatory responses are mediated by EGR-1/GGPPS/MAPK signaling.

Authors:  Ning Shen; Tao Gong; Jian-Dong Wang; Fan-Li Meng; Long Qiao; Run-Lin Yang; Bin Xue; Fei-Yan Pan; Xiao-Jun Zhou; Hua-Qun Chen; Wen Ning; Chao-Jun Li
Journal:  Am J Pathol       Date:  2010-12-23       Impact factor: 4.307

3.  Vitamin D deficiency, smoking, and lung function in the Normative Aging Study.

Authors:  Nancy E Lange; David Sparrow; Pantel Vokonas; Augusto A Litonjua
Journal:  Am J Respir Crit Care Med       Date:  2012-07-19       Impact factor: 21.405

4.  Vitamin D binding protein gene polymorphisms and chronic obstructive pulmonary disease: a meta-analysis.

Authors:  Huan Chen; Lei Zhang; Zhiyi He; Xiaoning Zhong; Jianquan Zhang; Meihua Li; Jing Bai
Journal:  J Thorac Dis       Date:  2015-08       Impact factor: 2.895

Review 5.  National Emphysema Treatment Trial state of the art: genetics of emphysema.

Authors:  Craig P Hersh; Dawn L DeMeo; Edwin K Silverman
Journal:  Proc Am Thorac Soc       Date:  2008-05-01

6.  Joint analysis of multiple phenotypes using a clustering linear combination method based on hierarchical clustering.

Authors:  Xueling Li; Shuanglin Zhang; Qiuying Sha
Journal:  Genet Epidemiol       Date:  2019-09-20       Impact factor: 2.135

Review 7.  Chronic obstructive pulmonary disease. 1: Susceptibility factors for COPD the genotype-environment interaction.

Authors:  A J Sandford; E K Silverman
Journal:  Thorax       Date:  2002-08       Impact factor: 9.139

8.  Lack of association of group specific component haplotypes with lung function in smokers.

Authors:  I Kasuga; P D Paré; J Ruan; J E Connett; N R Anthonisen; A J Sandford
Journal:  Thorax       Date:  2003-09       Impact factor: 9.139

Review 9.  Genetics of chronic obstructive pulmonary disease.

Authors:  Carola Seifart; Alexandra Plagens
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2007

10.  Chronic obstructive pulmonary disease: towards pharmacogenetics.

Authors:  Alice M Wood; See Ling Tan; Robert A Stockley
Journal:  Genome Med       Date:  2009-11-30       Impact factor: 11.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.